Second Sight Medical Products (NASDAQ:EYES) Stock Price Crosses Above the 50-Day Moving Average of $1.85
Shares of Second Sight Medical Products, Inc. (NASDAQ:EYES – Get Rating) rose above their fifty-day moving average during Thursday’s trading. The stock has a fifty-day moving average of $1.85 and is trading up to $2.32. Shares of Second Sight Medical Products last traded at $2.27, with volume traded at 166,640 shares.
Separately, StockNews.com upgraded Second Sight Medical Products to a “sell” rating in a Wednesday, March 30, research report.
The stock has a 50-day moving average of $1.85 and a two-hundred-day moving average of $1.62.
Second Sight Medical Products (NASDAQ:EYES – Get Rating) last reported results on Monday, March 28. The medical device company reported ($0.02) EPS for the quarter.
In other Second Sight Medical Products news, Director Gregg Williams purchased 74,870 shares of the company in a transaction that took place on Tuesday, May 31. The shares were purchased at an average cost of $2.33 per share, for a total transaction of $174,447.10. Following the completion of the purchase, the director now owns 10,936,326 shares of the company, valued at approximately $25,481,639.58. The purchase was disclosed in a filing with the SEC, which is available on the SEC’s website. Insiders have purchased 636,734 shares of the company worth $1,163,387 over the past 90 days. Insiders of the company hold 47.20% of the shares of the company.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Second Sight Medical Products by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company valued at $1,747,000 after buying an additional 17,164 shares in the last quarter. Renaissance Technologies LLC bought a new position in Second Sight Medical Products in the first quarter worth approximately $249,000. Finally, Squarepoint Ops LLC bought a new position in Second Sight Medical Products in the third quarter worth approximately $53,000. Institutional investors and hedge funds hold 9.09% of the company’s shares.
Second Sight Medical Products Company Profile (NASDAQ: EYES)
Second Sight Medical Products, Inc. develops, manufactures and markets implantable vision prostheses intended to provide artificial vision to people who are blind. It develops technologies to treat the population of visually impaired people. The Company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, intended to provide useful artificial vision to people who are blind due to a variety of causes, including glaucoma, diabetic retinopathy, optic nerve damage or disease, and eye damage.
Receive daily news and reviews for Second Sight medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Second Sight Medical Products and related companies with MarketBeat.com’s FREE daily newsletter.